Status:
COMPLETED
Selegiline for Smoking Cessation - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
VA Office of Research and Development
Conditions:
Nicotine Dependence
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Must be at least 18 years of age
- Be in good general health
- Must meet Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for nicotine dependence
- Be currently smoking \> 15 cigarettes/day, and have smoked cigarettes for the past 5 years
- Subjects must be motivated to quite smoking
- If female and of child bearing potential, agrees to use birth control and subject
- Subject must be able to understand and provide written informed consent.
- Exclusion
- Criteria:
- Please contact site for more information
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT00439413
Start Date
June 1 2007
End Date
January 1 2009
Last Update
February 2 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Public & Community Health
College Park, Maryland, United States, 20745
2
Robert Wood Johnson Med School-Tobacco Dep Program
New Brunswick, New Jersey, United States, 08901
3
Tri-State Tobacco and Alcohol Research Center
Cincinnati, Ohio, United States, 45237
4
Center For Tobacco Research and Intervention
Milwaukee, Wisconsin, United States, 53233